{"id":30650,"date":"2026-07-03T18:30:52","date_gmt":"2026-07-03T13:00:52","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?p=30650"},"modified":"2026-07-03T18:44:30","modified_gmt":"2026-07-03T13:14:30","slug":"your-dermatology-ar-over-90-days-is-not-dead","status":"publish","type":"post","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/your-dermatology-ar-over-90-days-is-not-dead\/","title":{"rendered":"Your Dermatology AR Over 90 Days Is Not Dead \u2014 It Is Misclassified"},"content":{"rendered":"

Dermatology AR aging past 90 days is not a collection failure \u2014 it is a classification failure, and the difference costs multi-provider dermatology groups an average of $180,000 to $340,000 per 12 months in revenue that gets written off as uncollectable before a single recovery attempt is made against the correct denial root cause.<\/p>\r\n

The standard practice management report labels anything more than 90 days old as “bad debt” or “write-off candidate.” MBC’s Revenue Integrity Framework<\/strong><\/a> labels it differently: misrouted cosmetic-versus-medical split denials, expired prior authorization appeals on biologics and phototherapy, unbundled excision and destruction claims sitting in a pending queue, and Modifier 25 rejections on E\/M visits performed same-day as a procedure \u2014 each of which has a defined recovery path that closes permanently the moment a write-off is posted.<\/p>\r\n

For a dermatology group billing $2M to $5M monthly, the 90-day AR bucket is not a graveyard. It is an unworked revenue queue disguised as one.<\/p>\r\n

\r\n

Why Dermatology AR Misclassification Happens<\/h2>\r\n

The Cosmetic-Versus-Medical Split Creates a Parallel Denial Category<\/h3>\r\n

Dermatology practices that bill both cosmetic and medical services operate under two fundamentally different reimbursement structures for the same patient, often on the same date of service. When a payer denies a medical dermatology claim \u2014 acne surgery under CPT 10040, destruction of benign lesions under CPT 17110, or biopsy under CPT 11102 \u2014 citing a cosmetic exclusion that does not apply to the submitted diagnosis, the denial lands in the AR aging report as a standard denial.<\/p>\r\n

Most billing teams route it to a generic denial queue. The correct route is a cosmetic exclusion appeal with diagnosis-specific medical necessity documentation \u2014 a fundamentally different process with a fundamentally different success rate. Misrouted into the standard denial workflow, these claims age past 90 days and get written off. Correctly identified and appealed, recovery rates run 60% to 80% on claims under 150 days old.<\/p>\r\n

A dermatology group processing 400 medical claims monthly with a 12% cosmetic exclusion misrouting rate is writing off $57,600 to $96,000 per 12 months in fully recoverable revenue, every dollar of which disappears the moment a write-off is posted without a denial root-cause<\/strong> audit first.<\/p>\r\n

Biologic and Phototherapy Prior Authorization Expiration<\/h3>\r\n

Dermatology biologics \u2014 dupilumab (Dupixent), secukinumab (Cosentyx), ustekinumab (Stelara) \u2014 carry the highest per-claim revenue events in outpatient dermatology and the most compressed prior authorization validity windows. When a biologic infusion or injection is administered after the authorization has expired due to a scheduling lag or an incomplete re-authorization workflow, the claim is denied as unauthorized.<\/p>\r\n

In a standard AR aging report, this denial sits in the same bucket as a routine coding error. It is not a coding error \u2014 it is a payer variance<\/strong> event requiring a specific corrective authorization request, not a standard appeal. Practices filing through the standard appeal path exhaust the remedy window without resolution. The claim is more than 90 days past due and is written off.<\/p>\r\n

For a dermatology group administering 30 biologic injections monthly, a 10% authorization expiration rate generates $18,000 to $54,000 per 12 months in claims sitting in the 90-day bucket that are recoverable through the correct corrective authorization process \u2014 but not through the standard denial appeal that most billing teams apply.<\/p>\r\n

Modifier 25 Rejections Sitting Unworked in the Aging Queue<\/h3>\r\n

When a dermatologist performs a significant, separately identifiable E\/M service on the same date as a minor procedure\u2014 such as excision, destruction, or biopsy \u2014Modifier 25 on the E\/M claim is the mechanism that preserves separate reimbursement. Payers who apply NCCI bundling edits to same-day E\/M and procedure claims without Modifier 25 generate denials that require a specific resubmission with modifier documentation \u2014 not a clinical appeal.<\/p>\r\n

These are among the fastest-turnaround recoverable denials in dermatology billing: median resolution of 14 to 21 days when correctly resubmitted. They are also among the most consistently misclassified in aging reports \u2014 labeled as “bundling denials” and routed to a coding review queue where they sit for 60 to 90 days before anyone acts, at which point payer resubmission windows are closing.<\/p>\r\n

At $85 to $140 per E\/M claim and a 15% Modifier 25 omission rate across 500 monthly procedure-day encounters, a dermatology group is carrying $51,000 to $126,000 per 12 months in Modifier 25 resubmission claims in its aging queue \u2014 recoverable in three weeks if correctly identified, permanently lost if written off.<\/p>\r\n

\r\n

The Three Dermatology AR Misclassification Patterns Driving Silent Write-Offs<\/h2>\r\n